Black Friday Get Elite for just $149.00 Claim Now

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Nov-12	Forget clinical cash burns: Why Exelixis is up 38% since June EXEL Investing.com
Nov-11	Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London KNSA GlobeNewswire
Nov-09	Immunocore to present at upcoming investor conferences IMCR GlobeNewswire
Nov-06	Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma IMCR +9.12% GlobeNewswire
Nov-06	Immunocore reports third quarter financial results and provides a business update IMCR +9.12% GlobeNewswire
Nov-05	Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress ALKS Business Wire
Nov-03	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November EXEL Business Wire
Nov-03	Alkermes to Present at Upcoming Investor Conferences ALKS Business Wire
Nov-03	Alkermes Beats Its Own Guidance, But Lybalvi Pricing Dilution And Takeda's Orexin Launch Cloud A Stronger Quarter ALKS Earnings Whispers
Nov-03	Alkermes: Q3 Earnings Snapshot ALKS Associated Press
Nov-03	Alkermes plc Reports Third Quarter 2026 Financial Results ALKS Business Wire
Oct-30	Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) ALKS Business Wire
Oct-29	Exelixis Matches The Whisper As Cabometyx Growth Accelerates, But Zanzalintinib Delays And Flat Guidance Temper A Stock Near Its Highs EXEL Earnings Whispers
Oct-29	Exelixis: Q3 Earnings Snapshot EXEL Associated Press
Oct-29	Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update EXEL Business Wire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)